8 Mg Perampanel May Be Best For Hard-To-Treat Seizures

What was studied

This study combined results from 4 randomized, double-blind, placebo-controlled trials of perampanel for people with refractory partial-onset seizures. In total, 2,187 participants were included. The researchers compared fixed doses of perampanel: 2 mg, 4 mg, 8 mg, and 12 mg, as well as placebo.

Because this was a network meta-analysis, the authors pooled data across trials to compare doses with each other, including some comparisons that were indirect rather than from head-to-head trials. They looked at how many people had their seizures reduced by at least 50%, how many became seizure-free, side effects, serious side effects, dropout rates due to side effects, and how many stayed on treatment.

What they found

In this analysis, 8 mg and 12 mg were associated with higher 50% responder rates than placebo and some lower doses. Doses of 4 mg, 8 mg, and 12 mg were also associated with higher seizure-free rates than placebo.

The 12 mg dose was associated with more treatment-emergent side effects than 4 mg, 2 mg, and placebo. No significant differences were found in serious treatment-emergent adverse events across groups. Dropout rates due to side effects were higher with 12 mg than with 8 mg, 4 mg, and placebo, and were also higher with 8 mg than with 4 mg and placebo. Retention on treatment was lower with 12 mg than with 4 mg, 8 mg, or placebo.

Based on these findings, the authors recommended 8 mg as the preferred first-line dose, with 12 mg as a secondary option when needed.

Limits of the evidence

This study pooled only 4 trials, so the evidence base was limited in size. A network meta-analysis can estimate comparisons between doses indirectly, which is useful, but it is not the same as having head-to-head trials of every dose.

The abstract does not provide much detail about participants' ages, other seizure medicines, length of follow-up, or whether results differed across patient subgroups. The authors also noted that their recommendations may not apply to all patients, especially those with unique clinical characteristics or specific clinical circumstances.

For families and caregivers

For families, this study suggests that perampanel may help reduce partial-onset seizures, and that 8 mg was identified by the authors as the preferred first-line dose among the fixed doses studied. A higher dose, such as 12 mg, was associated with better seizure outcomes in some comparisons, but also with more side effects, more treatment dropouts, and lower retention.

This does not mean one dose is right for everyone. Treatment decisions still depend on the individual patient, including other medicines, side effects, seizure control, and other health factors.

What to watch next

More direct dose-to-dose trials and studies reporting results in different patient groups would help clarify how these findings apply across clinical settings.

Terms in this summary

partial-onset seizures

Seizures that start in one area of the brain; they are also often called focal seizures.

refractory

Hard to control with treatment.

network meta-analysis

A study method that combines results from several trials to compare multiple treatments or doses at the same time.

placebo

An inactive treatment used for comparison in a clinical trial.

50% responder rate

The share of people whose seizure frequency dropped by at least half.

treatment-emergent adverse events

Side effects or unwanted problems that happen after starting the treatment.

serious adverse events

Side effects that are severe, medically important, or require urgent care or hospitalization.

retention rate

The share of people who stayed on the treatment during the study.